At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
ALXN1840 +1 moredrug
Likely dose
ALXN1840 60 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single-Center, Randomized, 3-Period Crossover Study to Evaluate the Relative Bioavailability of WTX101 in Healthy Subjects After Single Dose Administration of a Non-Coated Formulation With and Without a Proton Pump Inhibitor and With a Proton Pump Inhibitor With and Without Food
In Brief
A Phase 1 clinical trial evaluating ALXN1840 and Omeprazole for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Molybdenum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
Primary CompletionMar 2014
First PostedApr 2022
TodayJul 2026
First PostedApr 8, 2022
Enrollment StartJan 20, 2014
Primary CompletionMar 24, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.2 years ago
Interventions
ALXN1840drug
ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Omeprazoledrug
Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.